Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 QTc and PK Study of DS-8201a in HER2-Expressing Metastatic/Unresectable Breast Cancer
jRCT2080223735Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Effect of DS-8201a on QTc interval and Pharmacokinetics of DS-8201a. Started Nov 2017; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223735.